scholarly journals A possible case of serum sickness after ocrelizumab infusion – Commentary

2020 ◽  
Vol 27 (1) ◽  
pp. 158-159
Author(s):  
Sarmad Al-Araji ◽  
Olga Ciccarelli
Keyword(s):  
Multiple Sclerosis ◽  
Case Report ◽  
Hypersensitivity Reaction ◽  
Current Literature ◽  
Immune Complexes ◽  
Serum Sickness ◽  
The Third ◽  
Relapsing Remitting ◽  
Delayed Hypersensitivity Reaction ◽  
Relapsing Remitting Multiple Sclerosis

Serum sickness is a type III delayed hypersensitivity reaction which causes deposition of immune-complexes in the tissues. It has been reported with rituximab, and in this issue of the journal, there is a case report of a patient with relapsing remitting multiple sclerosis who developed a possible serum sickness after the third infusion of ocrelizumab. In this commentary, we discuss the current literature on serum sickness, and how to diagnose and manage it. We provide our opinion on this particular case, and encourage neurologists and patients to remain vigilant of such a possibility.

Cladribine transfer into human milk: A case report

2020 ◽  
pp. 135245852091217
Author(s):  
Palika Datta ◽  
Andrea I Ciplea ◽  
Kathleen Rewers-Felkins ◽  
Teresa Baker ◽  
Ralf Gold ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Mass Spectrometry ◽  
Case Report ◽  
Human Milk ◽  
Liquid Chromatography Mass Spectrometry ◽  
Milk Samples ◽  
First Case ◽  
Relapsing Remitting ◽  
Infant Dose ◽  
Relapsing Remitting Multiple Sclerosis

Background: Cladribine is an antimetabolite used for the treatment of relapsing–remitting multiple sclerosis. At present, there are no data available on its use in breastfeeding mothers and its transfer in human milk. Objective: We present a case of a lactating mother who donated her milk samples to study the transfer of cladribine following a 20-mg oral dose. Methods: Analysis was done using liquid chromatography–mass spectrometry. Results: The relative infant dose calculated in this study was 3.06%. Conclusion: This is the first case report suggesting the transfer of cladribine in human milk in measurable quantities. However, caution should be advised during lactation.

scholarly journals A Case Report of Relapsing Remitting Multiple Sclerosis: Getting the Diagnosis Sooner

2021 ◽  
Vol 8 (2) ◽  
Author(s):  
Fuentes S ◽  
Keyword(s):  
Multiple Sclerosis ◽  
Case Report ◽  
Early Diagnosis ◽  
Disease Process ◽  
Diagnosis And Treatment ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Multiple sclerosis can often present with nonspecific symptoms leading to difficulty in establishing a diagnosis early in the disease process. Early diagnosis and treatment is of importance due to the associated decrease in disability for those that get treatment sooner. Here we present a case with a patient the presented with changes in vision and paresthesias. Her initial workup from the neurologist was negative and further workup was delayed until her symptoms worsened. After worsening symptoms, MRI revealed that multiple sclerosis was the cause of her symptoms.

scholarly journals Acute myeloid leukaemia induced by mitoxantrone: case report

2005 ◽  
Vol 63 (2a) ◽  
pp. 327-329 ◽  
Author(s):  
Walter Oleschko Arruda ◽  
María Belén Montú ◽  
Marcelo de Souza R. de Oliveira ◽  
Ricardo Ramina
Keyword(s):  
Multiple Sclerosis ◽  
Case Report ◽  
Acute Myeloid Leukaemia ◽  
Progressive Multiple Sclerosis ◽  
White Female ◽  
Severe Thrombocytopenia ◽  
Relapsing Remitting ◽  
Low Incidence ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Acute Myeloid

Mitoxantrone (MX) is an immunosupressant drug used in secondarily progressive multiple sclerosis (SPMS) and in relapsing-remitting multiple sclerosis (RRMS). It has a leukemogenesis potential induced by cytogenetic abnormalities, though with a low incidence. Promyelocitic leukaemia (type M3) and other forms of acute myeloblastic leukaemias (M4 and M5) have been described in a few MS patients who received MX during their treatment. We describe a white female patient, 47 year-old, with SPMS (EDSS = 4) with 14 years of disease. She received MX during her disease and developed acute promyelocytic leukaemia (M3), with severe thrombocytopenia 30 months later. She ultimately died due to intracerebral hemorrhage. Other cases of treatment related to AML are reviewed and discussed.

scholarly journals DGI-037 Fingolimod in Relapsing Remitting Multiple Sclerosis: A Case Report

2013 ◽  
Vol 20 (Suppl 1) ◽  
pp. A109.1-A109
Author(s):  
M Merchante ◽  
A Izquierdo ◽  
S Martinez ◽  
AP Zorzano ◽  
L Sanchez-Rubio ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Case Report ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

scholarly journals Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy

2021 ◽  
Vol 47 (1) ◽  
Author(s):  
Elisabetta Godano ◽  
Fabio Barra ◽  
Alessandra Allodi ◽  
Antonella Ferraiolo ◽  
Alice Laroni ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Case Report ◽  
Unplanned Pregnancy ◽  
Critical Role ◽  
Highly Active ◽  
Relapsing Remitting ◽  
The Status ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Maternal Disease

Abstract Background Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be carefully evaluated only in women with highly active disease who plan a pregnancy or have an unplanned pregnancy, after accurate counseling about eventual maternal disease relapse due to therapy suspension. Case presentation This brief case report describes a case of documented anemia that we observed in a newborn whose mother with relapsing-remitting multiple sclerosis was treated with an extended dosing protocol of natalizumab throughout pregnancy. The newborn received the infusion of erythropoietin every seven days from the fortieth day of life; subsequently, the status of anemia underwent clinical resolution. Conclusions This case report confirmed that natalizumab can cause disorders of hematopoiesis, including anemia, thrombocytopenia, or pancytopenia, in newborns of patients treated during pregnancy. A multidisciplinary team, including experienced pediatricians and pediatric hematologists, has a critical role in managing newborns delivered by women, being treated with natalizumab for treating relapsing-remitting multiple sclerosis during pregnancy.

scholarly journals Rituximab induced cytokine release syndrome in an MS patient: a case report

2021 ◽  
Author(s):  
Masoud Etemadifar ◽  
Mehri Salari ◽  
Mahdieh Saeri ◽  
Amirhossein Akhavan Sigari ◽  
Sara Ebrahimi
Keyword(s):  
Multiple Sclerosis ◽  
Case Report ◽  
Side Effect ◽  
Signs And Symptoms ◽  
Common Side Effect ◽  
Cytokine Release ◽  
Cytokine Release Syndrome ◽  
Relapsing Remitting ◽  
History Of ◽  
Relapsing Remitting Multiple Sclerosis

Rituximab use in multiple sclerosis has been promising. Cytokine release syndrome (CRS) is a common side effect of rituximab in patients with lymphoma. We report a case of a 44-year-old man with a history of relapsing-remitting multiple sclerosis, who presented with signs and symptoms consistent with CRS after rituximab initiation.

Sign in / Sign up

Export Citation Format

Share Document